| Literature DB >> 25678818 |
Nahid Rianon1, Maureen E Knell2, Walter Agbor-Bawa3, Joan Thelen4, Crystal Burkhardt3, Rafia S Rasu3.
Abstract
OBJECTIVE: Due to the high risk of life-threatening side effects, nonsteroidal anti-inflammatory drugs (NSAIDs) are not favored for treating persistent nonmalignant pain in the elderly. We report national prescription trends with determinants of NSAIDs prescription for persistent nonmalignant pain among older patients (age 65 and over) in the US outpatient setting.Entities:
Keywords: AGS guideline; NAMCS; NSAIDs; inappropriate adjuvant; pain management
Year: 2015 PMID: 25678818 PMCID: PMC4319679 DOI: 10.2147/DHPS.S67425
Source DB: PubMed Journal: Drug Healthc Patient Saf ISSN: 1179-1365
Description of patient, physician, regional, and insurance characteristics for all patients versus those who received NSAIDs prescriptions (206 million weighted cross-sectional patients ≥65 years using NAMCS data from 2000 to 2007)
| Variables | Total patients (age ≥65 years)
| Patients with NSAID prescription (age ≥65 years)
|
|---|---|---|
| N=206,879,848 | N=185,390,143 | |
| Age (years) | ||
| Mean | 75.5 | 75.4 |
| SD (±) | 11.6 | 11.7 |
| Gender (%) | ||
| Male | 33.00% | 32.00% |
| Female | 67.00% | 68.00% |
| Region (%) | ||
| Northeast | 21.00% | 21.90% |
| Midwest | 22.00% | 21.40% |
| South | 36.00% | 35.90% |
| West | 21.00% | 20.80% |
| Race/ethnicity (%) | ||
| Hispanic | 7.10% | 7.10% |
| Non-Hispanic | 92.90% | 92.90% |
| White | 87.60% | 87.60% |
| Minority | 8.60% | 8.80% |
| Other | 3.80% | 3.70% |
| Payment source (%) | ||
| Medicare | 75.60% | 74.70% |
| Medicaid | 4.90% | 4.90% |
| Private insurance | 14.00% | 14.70% |
| Other insurance | 5.50% | 5.70% |
| Number of medications | ||
| Patients on ≤4 medications | 63.00% | 68.80% |
| Patients on ≥5 medications | 36.80% | 31.20% |
| Type of medications (%) | ||
| NSAIDs | 89.60% | 100.00% |
| Opioids | 10.80% | 10.40% |
| Adjuvant agent | 27.01% | 26.18% |
| Tricyclics | 1.30% | 1.28% |
| Other antidepressants/anticonvulsants | 12.70% | 11.90% |
| Antirheumatics | 1.30% | 1.30% |
| Muscle relaxant | 2.10% | 2.00% |
| Corticosteriods | 9.60% | 9.60% |
| Topical agents (capsaicin) | 0.04% | 0.04% |
| Type of pain reported (%) | ||
| Neuropathic pain | 3.75% | 3.37% |
| Muscle pain | 3.88% | 3.93% |
| Inflammatory pain | 27.80% | 27.95% |
| Mechanical pain | 13.61% | 13.73% |
| Two or more types of pain reported | 2.91% | 3.00% |
| PCP | 52.30% | 50.60% |
| Physician specialty (%) | ||
| Family practice | 21.40% | 20.90% |
| Internal medicine | 28.30% | 26.80% |
| Orthopedic surgery | 15.10% | 16.50% |
| Pain medicine | 0.10% | 0.10% |
| Psychiatry | 3.90% | 4.40% |
| Rheumatology | 6.00% | 6.40% |
| Geriatric medicine | 0.90% | 0.90% |
| Neurology | 1.30% | 1.30% |
| General practice | 2.40% | 2.50% |
| Other specialties | 20.70% | 20.20% |
| Established patient | 93.74% | 93.50% |
Notes: Physican specialty reports the distribution of visits to different specialties among those who received NSAIDs prescriptions.
Adjuvant agents include: tricyclic antidepressants, SSRIs, anticonvulsants, antirheumatics/immunologics, muscle relaxants, topical products (capsaicin), and corticosteroids;
other race includes African American, Asian/Native Hawaiian/Other Pacific Islander, American Indian/Alaskan Native, and cases where more than one race was reported.
Abbreviations: NAMCS, National Ambulatory Medical Care Survey; NSAIDs, nonsteroidal anti-inflammatory drugs; PCP, primary care provider; SD, standard deviation.
Figure 1Patients (aged ≥65 years) NSAIDs usage 2000–2007.
Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; P N MP, persistent non-malignant pain.
Logistic regression for factors influencing NSAIDs prescription in patients aged ≥65 years for treatment of persistent nonmalignant pain
| Variables | Patients (aged ≥65 years)
| ||
|---|---|---|---|
| N=5,968
| |||
| OR | 95% CI | ||
| Gender | |||
| Female | 1.79 | 1.37–2.33 | <0.0001 |
| Region | |||
| Northeast | 1 (reference) | ||
| West | 0.94 | 0.54–1.64 | 0.83 |
| Midwest | 0.63 | 0.41–0.97 | 0.04 |
| South | 0.95 | 0.61–1.46 | 0.8 |
| Race/ethnicity | |||
| White | 0.72 | 0.41–1.27 | 0.26 |
| Other race | 0.45 | 0.19–1.11 | 0.08 |
| African American | 1 (reference) | ||
| Hispanic | 0.66 | 0.40–1.08 | 0.1 |
| Non-Hispanic | 1 (reference) | ||
| Payment source | |||
| Medicare | 0.52 | 0.25–1.09 | 0.08 |
| Medicaid | 0.86 | 0.32–2.32 | 0.77 |
| Private insurance | 0.71 | 0.33–1.54 | 0.39 |
| Other insurance | 1 (reference) | ||
| Number of medications | |||
| Patients on ≤4 medications | 12.4 | 8.58–17.92 | <0.0001 |
| Established patient | 1.04 | 0.56–1.92 | 0.91 |
| PCP | 0.63 | 0.46–0.88 | <0.05 |
Notes:
Other race includes African American, Asian/Native Hawaiian/Other Pacific Islander, American Indian/Alaskan Native, and cases where more than one race was reported. The Adjusted Wald test was used for categorical variables. Reference = the comparison groups for regional interpretation.
Abbreviations: CI, confidence interval; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PCP, primary care provider.